Cargando…

The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn’s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation

BACKGROUND AND AIMS: Historical and emerging data implicate fungi in Crohn’s disease [CD] pathogenesis. However, a causal link between mycobiota, dysregulated immunity, and any impact of NOD2 variants remains elusive. This study aims to evaluate associations between NOD2 variants and faecal mycobiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Andrew, Stewart, Christopher J, Kennedy, Nicholas A, Lodge, John K, Tremelling, Mark, Probert, Chris S, Parkes, Miles, Mansfield, John C, Smith, Darren L, Hold, Georgina L, Lees, Charlie W, Bridge, Simon H, Lamb, Christopher A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095387/
https://www.ncbi.nlm.nih.gov/pubmed/33119074
http://dx.doi.org/10.1093/ecco-jcc/jjaa220
_version_ 1783688067113025536
author Nelson, Andrew
Stewart, Christopher J
Kennedy, Nicholas A
Lodge, John K
Tremelling, Mark
Probert, Chris S
Parkes, Miles
Mansfield, John C
Smith, Darren L
Hold, Georgina L
Lees, Charlie W
Bridge, Simon H
Lamb, Christopher A
author_facet Nelson, Andrew
Stewart, Christopher J
Kennedy, Nicholas A
Lodge, John K
Tremelling, Mark
Probert, Chris S
Parkes, Miles
Mansfield, John C
Smith, Darren L
Hold, Georgina L
Lees, Charlie W
Bridge, Simon H
Lamb, Christopher A
author_sort Nelson, Andrew
collection PubMed
description BACKGROUND AND AIMS: Historical and emerging data implicate fungi in Crohn’s disease [CD] pathogenesis. However, a causal link between mycobiota, dysregulated immunity, and any impact of NOD2 variants remains elusive. This study aims to evaluate associations between NOD2 variants and faecal mycobiota in CD patients and non-CD subjects. METHODS: Faecal samples were obtained from 34 CD patients [18 NOD2 mutant, 16 NOD2 wild-type] identified from the UK IBD Genetics Consortium. To avoid confounding influence of mucosal inflammation, CD patients were in clinical remission and had a faecal calprotectin <250 μg/g; 47 non-CD subjects were included as comparator groups, including 22 matched household [four NOD2 mutant] and 25 non-household subjects with known NOD2 genotype [14 NOD2 mutant] identified by the NIHR BioResource Cambridge. Faecal mycobiota composition was determined using internal transcribed spacer 1 [ITS1] sequencing and was compared with 16S rRNA gene sequences and volatile organic compounds. RESULTS: CD was associated with higher numbers of fungal observed taxonomic units [OTUs] [p = 0.033]. Principal coordinates analysis using Jaccard index [p = 0.018] and weighted Bray‐Curtis dissimilarities [p = 0.01] showed Candida spp. clustered closer to CD patients whereas Cryptococcus spp. clustered closer to non-CD. In CD, we found higher relative abundance of Ascomycota [p = 0.001] and lower relative abundance Basidiomycota [p = 0.019] phyla. An inverse relationship was found between bacterial and fungal Shannon diversity in NOD2 wild-type which was independent of CD [r = -0.349; p = 0.029]. CONCLUSIONS: This study confirms compositional changes in the gut mycobiota in CD and provides evidence that fungi may play a role in CD pathogenesis. No NOD2 genotype-specific differences were observed in the faecal mycobiota.
format Online
Article
Text
id pubmed-8095387
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80953872021-05-10 The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn’s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation Nelson, Andrew Stewart, Christopher J Kennedy, Nicholas A Lodge, John K Tremelling, Mark Probert, Chris S Parkes, Miles Mansfield, John C Smith, Darren L Hold, Georgina L Lees, Charlie W Bridge, Simon H Lamb, Christopher A J Crohns Colitis Original Articles BACKGROUND AND AIMS: Historical and emerging data implicate fungi in Crohn’s disease [CD] pathogenesis. However, a causal link between mycobiota, dysregulated immunity, and any impact of NOD2 variants remains elusive. This study aims to evaluate associations between NOD2 variants and faecal mycobiota in CD patients and non-CD subjects. METHODS: Faecal samples were obtained from 34 CD patients [18 NOD2 mutant, 16 NOD2 wild-type] identified from the UK IBD Genetics Consortium. To avoid confounding influence of mucosal inflammation, CD patients were in clinical remission and had a faecal calprotectin <250 μg/g; 47 non-CD subjects were included as comparator groups, including 22 matched household [four NOD2 mutant] and 25 non-household subjects with known NOD2 genotype [14 NOD2 mutant] identified by the NIHR BioResource Cambridge. Faecal mycobiota composition was determined using internal transcribed spacer 1 [ITS1] sequencing and was compared with 16S rRNA gene sequences and volatile organic compounds. RESULTS: CD was associated with higher numbers of fungal observed taxonomic units [OTUs] [p = 0.033]. Principal coordinates analysis using Jaccard index [p = 0.018] and weighted Bray‐Curtis dissimilarities [p = 0.01] showed Candida spp. clustered closer to CD patients whereas Cryptococcus spp. clustered closer to non-CD. In CD, we found higher relative abundance of Ascomycota [p = 0.001] and lower relative abundance Basidiomycota [p = 0.019] phyla. An inverse relationship was found between bacterial and fungal Shannon diversity in NOD2 wild-type which was independent of CD [r = -0.349; p = 0.029]. CONCLUSIONS: This study confirms compositional changes in the gut mycobiota in CD and provides evidence that fungi may play a role in CD pathogenesis. No NOD2 genotype-specific differences were observed in the faecal mycobiota. Oxford University Press 2020-10-29 /pmc/articles/PMC8095387/ /pubmed/33119074 http://dx.doi.org/10.1093/ecco-jcc/jjaa220 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Nelson, Andrew
Stewart, Christopher J
Kennedy, Nicholas A
Lodge, John K
Tremelling, Mark
Probert, Chris S
Parkes, Miles
Mansfield, John C
Smith, Darren L
Hold, Georgina L
Lees, Charlie W
Bridge, Simon H
Lamb, Christopher A
The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn’s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation
title The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn’s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation
title_full The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn’s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation
title_fullStr The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn’s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation
title_full_unstemmed The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn’s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation
title_short The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn’s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation
title_sort impact of nod2 genetic variants on the gut mycobiota in crohn’s disease patients in remission and in individuals without gastrointestinal inflammation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095387/
https://www.ncbi.nlm.nih.gov/pubmed/33119074
http://dx.doi.org/10.1093/ecco-jcc/jjaa220
work_keys_str_mv AT nelsonandrew theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT stewartchristopherj theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT kennedynicholasa theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT lodgejohnk theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT tremellingmark theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT probertchriss theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT parkesmiles theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT mansfieldjohnc theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT smithdarrenl theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT holdgeorginal theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT leescharliew theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT bridgesimonh theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT lambchristophera theimpactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT nelsonandrew impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT stewartchristopherj impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT kennedynicholasa impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT lodgejohnk impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT tremellingmark impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT probertchriss impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT parkesmiles impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT mansfieldjohnc impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT smithdarrenl impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT holdgeorginal impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT leescharliew impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT bridgesimonh impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation
AT lambchristophera impactofnod2geneticvariantsonthegutmycobiotaincrohnsdiseasepatientsinremissionandinindividualswithoutgastrointestinalinflammation